12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALD518: Phase II started

Bristol-Myers began a double-blind, placebo-controlled, dose-ranging international Phase IIb trial to evaluate ALD518 as induction and maintenance therapy in about 288 patients who have had an insufficient response to conventional therapy or who have failed anti-

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >